中国医药创新企业的全球化转型进程仍在持续加速。日前,信达生物发布公告,宣布与礼来制药达成战略合作,携手推进肿瘤及免疫领域创新药物的全球研发。当3.5亿美元预付款的数字在医药圈炸开时,信达生物与礼来的第七次握手,早已超越了普通商业合作的范畴。以往,跨国药企与中国药企合作模式中,“买管线”是主流逻辑。跨国药企通过支付预付款和里程碑付款,获得中国药企在研药物的海外权益。如今,传统的快速填补跨国药企的研发...
Source Link中国医药创新企业的全球化转型进程仍在持续加速。日前,信达生物发布公告,宣布与礼来制药达成战略合作,携手推进肿瘤及免疫领域创新药物的全球研发。当3.5亿美元预付款的数字在医药圈炸开时,信达生物与礼来的第七次握手,早已超越了普通商业合作的范畴。以往,跨国药企与中国药企合作模式中,“买管线”是主流逻辑。跨国药企通过支付预付款和里程碑付款,获得中国药企在研药物的海外权益。如今,传统的快速填补跨国药企的研发...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.